--- title: "Compass Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285201846.md" datetime: "2026-05-05T12:02:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285201846.md) - [en](https://longbridge.com/en/news/285201846.md) - [zh-HK](https://longbridge.com/zh-HK/news/285201846.md) --- # Compass Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.1. EBIT: As of FY2026 Q1, the actual value is USD -22.28 M. #### Net Loss Compass Therapeutics, Inc. reported a net loss of - $18.3 million for the three months ended March 31, 2026, compared to a net loss of - $16.6 million for the same period in 2025. The accumulated deficit reached - $449.5 million as of March 31, 2026. #### Operating Expenses Total operating expenses were $20.3 million for the three months ended March 31, 2026, an increase from $18.0 million in the prior year period. #### Research and Development (R&D) Expenses Research and development expenses increased by $0.3 million, or 3%, to $13.4 million for the three months ended March 31, 2026, compared to $13.1 million for the three months ended March 31, 2025. R&D expenses for Tovecimig were $5.5 million in 2026, down from $6.9 million in 2025. R&D expenses for CTX-471 were $2.6 million in 2026, up from $1.9 million in 2025. R&D expenses for CTX-8371 were $1.3 million in 2026, up from $0.9 million in 2025. R&D expenses for CTX-10726 were $1.4 million in 2026, up from $1.3 million in 2025. Personnel (R&D) expenses were $4.6 million in 2026, up from $3.2 million in 2025. General (R&D) expenses were $1.3 million in 2026, up from $1.2 million in 2025. Unallocated research and development expenses were $2.5 million in 2026, up from $2.0 million in 2025. #### General and Administrative (G&A) Expenses General and administrative expenses increased by $2.0 million, or 41%, to $6.9 million for the three months ended March 31, 2026, compared to $4.9 million in 2025, primarily driven by a $2.0 million increase in stock-based compensation expense. Personnel (G&A) expenses were $4.9 million in 2026, up from $3.3 million in 2025. General (G&A) expenses were $2.0 million in 2026, up from $1.6 million in 2025. #### Interest Income Interest income was $2.0 million for the three months ended March 31, 2026, compared to $1.3 million for the same period in 2025. #### Cash Flow Net cash used in operating activities was - $17.3 million for the three months ended March 31, 2026, compared to - $13.2 million for the same period in 2025. Net cash provided by investing activities was $38.4 million for the three months ended March 31, 2026, compared to $11.6 million for the same period in 2025. Net cash provided by financing activities was $3.4 million for the three months ended March 31, 2026, compared to - $0.8 million for the same period in 2025. #### Liquidity and Capital Resources As of March 31, 2026, Compass Therapeutics, Inc. held $195 million in cash, cash equivalents, and marketable securities, which are estimated to fund operating expenses and capital expenditure requirements into 2028. #### Stock-Based Compensation Total stock-based compensation expense was $5.1 million for the three months ended March 31, 2026, compared to $2.5 million for the same period in 2025. The remaining unrecognized stock-based compensation cost was $50.0 million as of March 31, 2026, expected to be recognized over a weighted average period of 1.6 years. #### Outlook and Strategy Compass Therapeutics, Inc. anticipates incurring significant expenses for several years to advance clinical development, develop new product candidates, and pursue regulatory approval. The company will require substantial additional funding to support its operations and growth strategy, aiming to secure financing through equity and debt, collaborations, or other strategic transactions. The timing and amount of future operating expenditures are contingent on the progress and costs of clinical trials, regulatory approvals, intellectual property maintenance, and market acceptance of approved product candidates. ### Related Stocks - [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md) ## Related News & Research - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [GE Vernova Declares Third Quarter 2026 Dividend | GEV Stock News](https://longbridge.com/en/news/286966387.md) - [BSR REIT Announces May 2026 Cash Distribution](https://longbridge.com/en/news/286615296.md)